The quarterly print was essentially in line, with a narrow adjusted-EPS beat. Adjusted net loss was $1.07 per share versus a published consensus near $1.08 per share, making the financial result a technical Beat rather than a major earnings surprise. GAAP loss widened to $78.9 million from $45.3 million year over year, while operating expenses rose to $66.1 million from $44.0 million as commercialization spending ramped. (Financial Results; Reconciliation of GAAP Net Loss)
| Metric | Q2 2026 | Q2 2025 / reference | Read-through |
|---|---|---|---|
| Adjusted net loss per share | $(1.07) | $(0.93) | Narrowly better than approximately $(1.08) consensus |
| GAAP net loss | $(78.9M) | $(45.3M) | Loss increased with launch investment |
| Operating expenses | $66.1M | $44.0M | Up $22.1M year over year |
| SG&A expense | $35.0M | $7.6M | $23.4M of the increase was launch-related |
| Cash used in operations | $55.4M | $36.2M | Burn accelerated |
| Cash, equivalents and short-term investments | $754.0M | — | Management says runway extends into 2029 |
The real event is the transition from development company to commercial launch. REVTORPYK was FDA-approved on July 14, 2026, the NCCN Guidelines subsequently listed it as a preferred Category 1 option, and the company says commercial infrastructure is complete with shipments expected late in the third quarter. Those milestones were already disclosed before this filing, so the filing mostly confirms execution rather than creating a fresh regulatory surprise. (Clinical Highlights — 2nd Line Setting; Other Recent Developments)
The mutant-cohort data materially broadens the opportunity beyond the initial approval. In PIK3CA-mutant patients, the gedatolisib triplet cut the risk of progression or death by 50% versus alpelisib plus fulvestrant, with median progression-free survival of 11.1 months versus 5.6 months; the doublet produced a similar 49% risk reduction. Discontinuation due to adverse events was also lower for gedatolisib regimens than for alpelisib. The planned third-quarter sNDA gives this already-public data a clear regulatory next step. (Clinical Highlights — 2nd Line Setting — PIK3CA Mutant-Type)
The balance sheet removes near-term funding pressure but reflects a heavier cost structure. Celcuity raised $575.0 million of convertible notes, received $557.2 million net, and used $137.0 million to prepay term-loan debt. That financing supports the launch and expanded VIKTORIA-2 program, but quarterly operating cash burn rose to $55.4 million and the company has not yet reported product revenue. (Other Recent Developments; Cash Flow and Financial Results)
Net: a modest earnings beat paired with a stronger strategic picture, but most of the headline catalysts were already known. Against the market's immediate earnings benchmark, this was slightly better than expected; the more important change is that Celcuity now has an approved product, launch timing, and a credible path to expand the label into PIK3CA-mutant disease. The filing is therefore moderately positive overall, but not a wholly new surprise.
Read the original 8-K on SEC EDGAR ↗